

Press release

Foundation to promote leukemia research

Prof. Torsten Haferlach establishes non-profit leukemia diagnostics foundation

Munich, June 27, 2018. To promote science and research in the field of leukemia diagnostics, Prof. Torsten Haferlach of the MLL Munich Leukemia Laboratory has established the *Torsten Haferlach-Leukämiediagnostik-Stiftung* ("Torsten Haferlach Leukemia Diagnostics Foundation"). The aim of the foundation is to promote public health and public health care in the field of applied and patient-centered leukemia diagnostics in order to provide as many patients as possible with access to the best possible diagnostics and treatment.


Knowledge about the classification, prognosis, and treatment of leukemias and lymphomas has increased significantly over the past ten years. However, unambiguous diagnosis and subsequent treatment still present physicians and patients with complex challenges. With the *Torsten Haferlach-Leukämiediagnostik-Stiftung*, Prof. Torsten Haferlach, a hematologist and one of the managing directors of the MLL Munich Leukemia Laboratory, has dedicated himself to the task of promoting and advancing research and routine diagnostics in the field of leukemia diagnostics. By awarding fellowships for research and development work and by supporting worldwide projects in the field of leukemia diagnostics, the foundation will make major contributions to patient-centered leukemia diagnostics. This will also include infrastructure projects.

The researchers at MLL have contributed to a broad variety of scientific issues within hematology for more than 20 years, especially through the MLL Munich Leukemia Laboratory's international networks with other diagnostic laboratories and research groups around the world. "We believe that our central task is to encourage discussion of our knowledge, data, and findings, and to place them at the disposal of the scientific community through lectures/presentations, training, and publications. With the newly established *Torsten Haferlach-Leukämiediagnostik-Stiftung*, we would also like to offer other scientists the opportunity to conduct intensive research and to make a decisive contribution to leukemia research with their research results. We will also support the establishment of additional laboratories with know-how and equipment," said Prof. Haferlach.

The possible funding period for fellowship holders, for example, is between three months and two years. During this time, fellows will have the opportunity to perform scientific analyses on a data set of 5,000 cases of genome-sequenced leukemia and lymphoma disease at the MLL Munich Leukemia Laboratory.

Press contact

MLL Münchner Leukämielabor GmbH, Press Office, Kristina Kneis, Max-Lebsche-Platz 31, 81377 Munich
Phone +49 (0)89 99017 506, Email: presse@mll.com; www.mll.com



The aim of the projects should also be to improve approaches to the specific diagnosis of the diseases, to question general classification criteria, and in particular to uncover and redefine pathophysiological relationships. Every advance made will be applied to better routine care.

More information is available at: www.torsten-haferlach-leukaemiediagnostik-stiftung.de or www.thlds.de

Torsten Haferlach-Leukämiediagnostik-Stiftung

The Torsten Haferlach-Leukämiediagnostik-Stiftung is a non-profit foundation founded in 2018 that supports research and infrastructure projects in the field of leukemia diagnostics. The foundation was established by Prof. Torsten Haferlach, who is the founder of the MLL Munich Leukemia Laboratory and has been involved in hematology research and patient care since he was a medical student. In 1996, Haferlach completed his postdoctoral qualification (Habilitation) in internal medicine, with a focus on hematology and internal oncology, and in 2005 he worked as a senior physician at various German university clinics. The foundation enables scientists and others from all over the world to conduct intensive research and thus gain new insights into leukemia diagnostics and patient-centered therapy.

Press contact

MLL Münchner Leukämielabor GmbH, Press Office, Kristina Kneis, Max-Lebsche-Platz 31, 81377 Munich
Phone +49 (0)89 99017 506, Email: presse@mll.com; www.mll.com